Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA:603392)
China
· Delayed Price · Currency is CNY 39.35
+0.06 (0.15%)
Apr 29, 2026, 11:29 AM CST
SHA:603392 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 1,766 | 2,215 | 5,493 | 11,167 | 5,702 | Upgrade
|
| Other Revenue | 53.35 | 30.31 | 17.3 | 18.52 | 48.34 | Upgrade
|
| Revenue | 1,819 | 2,245 | 5,511 | 11,185 | 5,750 | Upgrade
|
| Revenue Growth (YoY) | -18.99% | -59.25% | -50.73% | 94.51% | 144.25% | Upgrade
|
| Cost of Revenue | 1,127 | 866.34 | 1,084 | 1,198 | 850.67 | Upgrade
|
| Gross Profit | 691.8 | 1,379 | 4,427 | 9,987 | 4,900 | Upgrade
|
| Selling, General & Admin | 836.46 | 790.16 | 1,878 | 3,490 | 1,874 | Upgrade
|
| Research & Development | 550.36 | 874.57 | 1,177 | 1,091 | 677.42 | Upgrade
|
| Other Operating Expenses | 12.46 | 14.67 | 31.57 | 51.28 | 26.71 | Upgrade
|
| Operating Expenses | 1,422 | 1,691 | 3,063 | 4,723 | 2,662 | Upgrade
|
| Operating Income | -730.56 | -312.22 | 1,364 | 5,265 | 2,238 | Upgrade
|
| Interest Expense | -6.46 | -8.32 | -6.86 | -7.67 | -5.69 | Upgrade
|
| Interest & Investment Income | 99.11 | 169.09 | 186.88 | 78.26 | 21 | Upgrade
|
| Currency Exchange Gain (Loss) | -14.47 | 7.42 | 13.01 | 27.89 | -8.75 | Upgrade
|
| Other Non Operating Income (Expenses) | -4.77 | -8.92 | -1.87 | -1 | 0.05 | Upgrade
|
| EBT Excluding Unusual Items | -657.15 | -152.95 | 1,555 | 5,362 | 2,244 | Upgrade
|
| Gain (Loss) on Sale of Investments | 48.3 | 36.71 | 24.66 | 9.98 | 0.03 | Upgrade
|
| Gain (Loss) on Sale of Assets | 58.04 | 7.39 | -1.08 | -2.74 | -0.97 | Upgrade
|
| Asset Writedown | - | - | -259.15 | - | - | Upgrade
|
| Other Unusual Items | 69.93 | 176.33 | 73.7 | 213.42 | 80.85 | Upgrade
|
| Pretax Income | -480.89 | 67.48 | 1,393 | 5,583 | 2,324 | Upgrade
|
| Income Tax Expense | -66.92 | -41.61 | 146.89 | 719.39 | 244.93 | Upgrade
|
| Earnings From Continuing Operations | -413.96 | 109.09 | 1,247 | 4,863 | 2,079 | Upgrade
|
| Minority Interest in Earnings | 15.7 | -2.86 | 1.18 | -127.51 | -57.75 | Upgrade
|
| Net Income | -398.27 | 106.24 | 1,248 | 4,736 | 2,021 | Upgrade
|
| Net Income to Common | -398.27 | 106.24 | 1,248 | 4,736 | 2,021 | Upgrade
|
| Net Income Growth | - | -91.48% | -73.65% | 134.28% | 198.59% | Upgrade
|
| Shares Outstanding (Basic) | 1,285 | 1,328 | 1,260 | 1,250 | 1,230 | Upgrade
|
| Shares Outstanding (Diluted) | 1,285 | 1,328 | 1,260 | 1,250 | 1,230 | Upgrade
|
| Shares Change (YoY) | -3.25% | 5.37% | 0.86% | 1.55% | 2.96% | Upgrade
|
| EPS (Basic) | -0.31 | 0.08 | 0.99 | 3.79 | 1.64 | Upgrade
|
| EPS (Diluted) | -0.31 | 0.08 | 0.99 | 3.79 | 1.64 | Upgrade
|
| EPS Growth | - | -91.92% | -73.88% | 130.69% | 190.01% | Upgrade
|
| Free Cash Flow | -715.41 | -532.27 | 378.15 | 3,203 | 634.16 | Upgrade
|
| Free Cash Flow Per Share | -0.56 | -0.40 | 0.30 | 2.56 | 0.52 | Upgrade
|
| Dividend Per Share | - | - | 0.320 | 0.714 | 0.099 | Upgrade
|
| Dividend Growth | - | - | -55.20% | 624.44% | 12.04% | Upgrade
|
| Gross Margin | 38.03% | 61.42% | 80.34% | 89.29% | 85.21% | Upgrade
|
| Operating Margin | -40.16% | -13.91% | 24.75% | 47.07% | 38.91% | Upgrade
|
| Profit Margin | -21.89% | 4.73% | 22.64% | 42.34% | 35.15% | Upgrade
|
| Free Cash Flow Margin | -39.33% | -23.71% | 6.86% | 28.63% | 11.03% | Upgrade
|
| EBITDA | -446.52 | -51.51 | 1,579 | 5,401 | 2,334 | Upgrade
|
| EBITDA Margin | -24.55% | -2.29% | 28.66% | 48.28% | 40.59% | Upgrade
|
| D&A For EBITDA | 284.04 | 260.71 | 215.29 | 136.17 | 96.2 | Upgrade
|
| EBIT | -730.56 | -312.22 | 1,364 | 5,265 | 2,238 | Upgrade
|
| EBIT Margin | -40.16% | -13.91% | 24.75% | 47.07% | 38.91% | Upgrade
|
| Effective Tax Rate | - | - | 10.54% | 12.89% | 10.54% | Upgrade
|
| Revenue as Reported | 1,819 | 2,245 | 5,511 | 11,185 | 5,750 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.